Changes in laboratory measures on voxelotor
| . | Wk 4 . | Wk 8 . | Wk 12 . |
|---|---|---|---|
| dHb, g/dL | 1.2 (0.4-1.5)∗ | 0.9 (0.4-1.2)∗ | 0.8 (0.2-1.4)∗ |
| dRetic, % | −2.8 (−3.3 to −0.7)† | −1.2 (−4.2 to 0.1)† | −1.4 (−2.5 to −0.4)† |
| dWBC, 1000/μL | −1.0 (−1.2 to −0.2)† | 0.4 (−2.0 to 1.4) | −0.8 (−1.6 to −0.1)∗ |
| dLDH, U/L | — | — | 27 (−10 to 64) |
| dBilirubin, μmol/L | — | — | −0.9 (−1.3 to −0.5)‡ |
| . | Wk 4 . | Wk 8 . | Wk 12 . |
|---|---|---|---|
| dHb, g/dL | 1.2 (0.4-1.5)∗ | 0.9 (0.4-1.2)∗ | 0.8 (0.2-1.4)∗ |
| dRetic, % | −2.8 (−3.3 to −0.7)† | −1.2 (−4.2 to 0.1)† | −1.4 (−2.5 to −0.4)† |
| dWBC, 1000/μL | −1.0 (−1.2 to −0.2)† | 0.4 (−2.0 to 1.4) | −0.8 (−1.6 to −0.1)∗ |
| dLDH, U/L | — | — | 27 (−10 to 64) |
| dBilirubin, μmol/L | — | — | −0.9 (−1.3 to −0.5)‡ |
Data are reported as median (IQR). P values were obtained from a 2-sided paired Wilcoxon signed-rank test.
dBilirubin, changes from pretreatment levels in bilirubin at 4, 8, and 12 wk of treatment; dHb, changes from pretreatment levels in Hb at 4, 8, and 12 wk of treatment; dLDH, changes from pretreatment levels in LDH at 4, 8, and 12 wk of treatment; dRetic, changes from pretreatment levels in reticulocytes at 4, 8, and 12 wk of treatment; dWBC, changes from pretreatment levels in white blood cell count at 4, 8, and 12 wk of treatment.
P < .05.
P < .01.
P < .005.